PharmEng has Received Notice of Reclassification to Tier 2 Issuer Status

WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), reports that Dr. Vivien Boniuk, Associate Professor of Ophthalmology, Albert Einstein College of Medicine, associated with the North Shore Long Island Jewish Health System (NSLIJ), will be presenting additional results from the animal studies on nanoviricide drug candidates against Epidemic Kerato-Conjunctivitis (EKC). These studies were conducted at the Feinstein Institute for Medical Research of the NSLIJ. Dr. Boniuk will be speaking at the GTC-Bio Conference on Ocular Diseases and Drug Discovery on April 21 in Philadelphia, PA.